Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective

OBJECTIVES: Using individual patient-level data from the phase 3 VIALE-A trial, this study assessed the cost-effectiveness of venetoclax in combination with azacitidine compared with azacitidine monotherapy for patients newly diagnosed with acute myeloid leukemia (AML) who are ineligible for intensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratz, Keith W., Chai, Xinglei, Xie, Jipan, Yin, Lei, Nie, Xiaoyu, Montez, Melissa, Iantuono, Erica, Downs, Lisa, Ma, Esprit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300490/
https://www.ncbi.nlm.nih.gov/pubmed/35696071
http://dx.doi.org/10.1007/s40273-022-01145-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300490/
https://www.ncbi.nlm.nih.gov/pubmed/35696071
http://dx.doi.org/10.1007/s40273-022-01145-7

Ejemplares similares